New business is being written on visibly better terms than the company's own recent norm, and the mix shift has just beg
The model's full reasoning — Q3 2018 call → NOWe need to answer YES or NO based on the transcript. The question asks about whether management indicates that economic terms of the newest business have stepped up meaningfully above the company's own recent norm, and that this improvement has only begun to flow into reported results because most business in reported numbers was still written at older terms. We need to look for evidence in the transcript. The company is Amgen, a biopharma. The "newest business" could refer to new product launches, biosimilars, or pricing changes. The question specifically asks about "prices, rates, fees, spreads, contract sizes, durations, or profitability" of recent deals, orders, contracts, renewals, or transactions. In the transcript, there is discussion about Repatha pricing. Murdo Gordon says: "we made an important decision to improve the access and affordability of Repatha especially for Medicare Part D patients... We've launched a new NDC at a list price of $5,850 which was the only viable option to reduce out-of-pocket cost for Medicare patients... Although the lower price may impact Repatha sales near term, as plans update we expect to see a positive impact on volume growth as this important therapy becomes more accessible and affordable for many more patients." This is about lowering price, not stepping up. So that's not it. Aimovig launch: strong uptake, but no mention of better terms than recent norm. It's a new product, but the question is about terms of business improving versus company's own recent past. The company is launching new products, but that's not necessarily about better pricing on existing business. Biosimilars: they are launching biosimilars, but no mention of better terms.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| CRBG | Corebridge Financial, Inc. | Q4 2022 | 2023-02-22 | B |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| MTB | M&T Bank Corporation | Q2 2022 | 2022-07-20 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
CRL · Q2 2022 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management's comments on Safety Assessment pricing and backlog directly address both required elements: they describe current bookings and backlog at "escalating prices" and "meaningful price increases" that are already achieved on real transactions (not targets or future expectations), while noting that the reported Q2 results are still dominated by older 2022 terms and that the stronger pricing is accelerating into H2 and 2023 bookings.
ESS · Q2 2018 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management describes the loss-to-lease metric rising to 3.
CTO · Q2 2023 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...